Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immunocore Holdings plc
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
October 29, 2026
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
October 15, 2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
September 14, 2026
Immunocore to present at upcoming investor conferences
September 1, 2026
Immunocore reports second quarter financial results and provides a business update
August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
July 30, 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
May 31, 2026
Immunocore reports first quarter financial results and provides a business update
May 7, 2026